Mayo Clinic and Stanford Medicine unveiled a blood test intended to map tumor “neighborhoods” via a noninvasive readout of the tumor microenvironment, aiming to predict immunotherapy response. The approach is positioned as a step beyond conventional liquid biopsy by decoding signaling and cellular ecosystem patterns associated with tumor behavior. The reported strategy uses a blood-based profiling workflow designed to capture deeper microenvironment information that can inform treatment selection. In precision oncology, the practical endpoint is whether such profiles can stratify patients for likely responders and reduce exposure to ineffective immunotherapies. The translational challenge will be clinical validation across cancer types, standardized sample handling, and demonstrating that the test’s predictions improve outcomes when used prospectively. If successful, the platform could widen the role of liquid biopsy from tumor genomics toward functional tumor ecology, influencing how trials and clinical decision-making are structured.